SCHEMBL25696301

SCHEMBL25696301

Cc1ccc2c(N)nn(C(C)(C)C)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 4/20 0.39
▸ HPGD P15428 5/20 0.38
▸ ALDH1A1 P00352 5/20 0.38
▸ SRC P12931 3/20 0.38
▸ ABL1 P00519 2/20 0.38
▸ KDR P35968 2/20 0.38
▸ RIPK2 O43353 2/20 0.38
▸ PDGFRA P16234 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ PLK4 O00444 1/20 0.38
▸ ROCK2 O75116 1/20 0.38
▸ PRKD3 O94806 1/20 0.38
▸ MAP4K4 O95819 1/20 0.38
▸ EGFR P00533 1/20 0.38
▸ ERBB2 P04626 1/20 0.38
▸ INSR P06213 1/20 0.38
▸ LCK P06239 1/20 0.38
▸ FYN P06241 1/20 0.38
▸ CSF1R P07333 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23930949 0.81 RET (0.42) RETSRCABL1KDRRIPK2
SCHEMBL25696308 0.79 ALDH1A1 (0.36) RETHPGDALDH1A1SRCABL1
SCHEMBL4420492 0.77 PRKD3 (0.43) RETHPGDALDH1A1SRCABL1
SCHEMBL8233002 0.77 ADORA2A (0.44) ALDH1A1KDRPDGFRACDK5TYRO3
SCHEMBL16158006 0.72 ADORA2A (0.49) HPGDALDH1A1PDGFRAKDM4ELMNA
SCHEMBL27051630 0.72 RET (0.38) RETHPGDALDH1A1SRCABL1
SCHEMBL15195161 0.70 SMN1; SMN2 (0.42) HPGDALDH1A1LMNAEGFRHTT
SCHEMBL19373835 0.67 CYP1A2 (0.35) HPGDALDH1A1KDM4ELMNAEGFR
SCHEMBL12326828 0.66 TDP1 (0.40) HPGDALDH1A1KDRKDM4ELCK
SCHEMBL25696305 0.64 KMO (0.45) RETHPGDALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF KRAS, NRAS, TP53 RET 14/4885HPGD 2426/4885ALDH1A1 3223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback